Open Data In Clinical Research
•
2 likes•509 views
Clinical trial registration aims to improve research by increasing transparency. It allows patients to find relevant trials, prevents duplication of efforts, and collaboration. While registration is now mandatory for clinical drug trials and publications, the author argues it could also benefit basic research by increasing opportunities for data sharing and reducing bias.
Report
Share
Report
Share
Download to read offline
Recommended
Safety Data Exchange Agreements (Brief)
Safety Data Exchange Agreements (Brief)
An integral part of enterprise risk management systems
Strategic management framework
Governance model
Standards, mechanisms, and metrics for management oversight
Roles and responsibilities
Stakeholder collaboration
Procedural documents and SDEA templates
CAPA management processes
Supporting systems
Document repositories
GXP Inspection readiness
Arete-Zoe is a consulting firm that provides services related to risk management in the pharmaceutical industry. They help clients address issues in clinical research, healthcare systems, and public health. Arete-Zoe analyzes vulnerabilities and provides recommendations to improve organizational effectiveness, business resiliency, and safety. Their services include assessing risks from manufacturing and supply chain issues, inspections, clinical trials, and other factors that can undermine the pharmaceutical industry.
Stem cells: Information environment
Alternative way of generating data from stem cells interventions performed under 21 CFR part 1271 (CGTP)
https://www.aretezoe.com/stem-cells
Ich
The International Council for Harmonisation (ICH) is a joint initiative between regulators and the pharmaceutical industry to harmonize technical requirements for drug registration. The goal is to streamline development, eliminate redundant testing, and make new medicines available more quickly while maintaining standards of safety and efficacy. ICH involves six regulatory and industry parties working to produce unified guidelines for the European Union, Japan, and United States on quality, safety, and efficacy. This helps facilitate mutual acceptance of clinical data between jurisdictions.
ICSR Narrative Writing_Katalyst HLS
Introduction to ICSR Narrative Writing in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
The document discusses the International Conference on Harmonization (ICH), an initiative to harmonize technical requirements for pharmaceutical registration. It describes ICH's mission to reduce redundant testing, outlines its structure and members, and explains the guidelines and regulatory requirements of various countries and regions, including the EU, MHRA, TGA, and rest of world.
Controlled release drug delivery market offers unexplored opportunities
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
Analysing the EU PVG regulations
This document summarizes the key principles and regulations of pharmacovigilance in the European Union. It discusses the basis and definitions of pharmacovigilance, the major milestones in EU pharmacovigilance legislation, and the roles and responsibilities of the European Medicines Agency, national competent authorities, marketing authorization holders, and other stakeholders in monitoring the safety of medicines in both pre- and post-authorization phases.
Recommended
Safety Data Exchange Agreements (Brief)
Safety Data Exchange Agreements (Brief)
An integral part of enterprise risk management systems
Strategic management framework
Governance model
Standards, mechanisms, and metrics for management oversight
Roles and responsibilities
Stakeholder collaboration
Procedural documents and SDEA templates
CAPA management processes
Supporting systems
Document repositories
GXP Inspection readiness
Arete-Zoe is a consulting firm that provides services related to risk management in the pharmaceutical industry. They help clients address issues in clinical research, healthcare systems, and public health. Arete-Zoe analyzes vulnerabilities and provides recommendations to improve organizational effectiveness, business resiliency, and safety. Their services include assessing risks from manufacturing and supply chain issues, inspections, clinical trials, and other factors that can undermine the pharmaceutical industry.
Stem cells: Information environment
Alternative way of generating data from stem cells interventions performed under 21 CFR part 1271 (CGTP)
https://www.aretezoe.com/stem-cells
Ich
The International Council for Harmonisation (ICH) is a joint initiative between regulators and the pharmaceutical industry to harmonize technical requirements for drug registration. The goal is to streamline development, eliminate redundant testing, and make new medicines available more quickly while maintaining standards of safety and efficacy. ICH involves six regulatory and industry parties working to produce unified guidelines for the European Union, Japan, and United States on quality, safety, and efficacy. This helps facilitate mutual acceptance of clinical data between jurisdictions.
ICSR Narrative Writing_Katalyst HLS
Introduction to ICSR Narrative Writing in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
The document discusses the International Conference on Harmonization (ICH), an initiative to harmonize technical requirements for pharmaceutical registration. It describes ICH's mission to reduce redundant testing, outlines its structure and members, and explains the guidelines and regulatory requirements of various countries and regions, including the EU, MHRA, TGA, and rest of world.
Controlled release drug delivery market offers unexplored opportunities
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
Analysing the EU PVG regulations
This document summarizes the key principles and regulations of pharmacovigilance in the European Union. It discusses the basis and definitions of pharmacovigilance, the major milestones in EU pharmacovigilance legislation, and the roles and responsibilities of the European Medicines Agency, national competent authorities, marketing authorization holders, and other stakeholders in monitoring the safety of medicines in both pre- and post-authorization phases.
Pharmacovigilance systems & methodologies across the globe
The document discusses various pharmacovigilance systems and methodologies used around the world to monitor the safety of medicines. It describes the WHO global database VigiBase which contains reports of adverse drug reactions. It also outlines other pharmacovigilance systems like EudraVigilance in Europe, FAERS in the US, Canada Vigilance in Canada, and the Yellow Card Scheme in the UK. The document then discusses data mining and analysis techniques used for pharmacovigilance, including those for pre-marketing surveillance using computational approaches as well as those for post-marketing surveillance using spontaneous reporting systems, electronic health records, and non-traditional data sources.
Market impact of WHO selection and prequalification of priority medicines
Presentation with the occasion of the Technical Briefing at World Halth Assembly, Geneva, 18 May 2011
Pharmacovigilance
Pharmacovigilance is the science of monitoring approved drugs to detect adverse effects. It aims to improve patient safety by understanding drug risks. Clinical trials cannot detect all risks due to limited size and duration. Spontaneous reporting allows healthcare providers to report suspected adverse drug reactions. Limitations of clinical data and withdrawals like thalidomide led to pharmacovigilance programs worldwide including the WHO program and national programs in India, UK, and US. Pharmacovigilance involves collecting, analyzing, and communicating safety information to improve patient therapy and public health.
Pharmacovigilance - a regulator's perspective
The document discusses pharmacovigilance from the perspective of the Therapeutic Goods Administration (TGA) in Australia. It provides an overview of the TGA's pharmacovigilance activities, including pre-market risk management plans and post-market adverse event reporting and signal detection. It describes how the TGA monitors the safety of medicines throughout their lifecycle to identify new or unknown risks following approval.
Post marketing servillence
This document discusses post-marketing surveillance (PMS), which involves monitoring the safety of pharmaceutical drugs and medical devices after they have been approved and released on the market. PMS is important because pre-approval clinical trials involve limited numbers of patients and cannot detect all potential adverse effects. The document outlines the history of PMS, sources of PMS information, benefits of PMS systems, methods of surveillance including spontaneous reporting and cohort studies, and how manufacturers can establish PMS procedures and systems to gather feedback on their products.
Literature monitoring for pv what are we doing at galderma elsevier webinar
The document discusses literature monitoring for pharmacovigilance. It describes weekly monitoring of individual case safety reports and periodic monitoring through development safety update reports and periodic benefit-risk evaluation reports. Key databases for literature searches are Medline and Embase. While Embase has more extensive drug coverage, searches on Medline via PubMed are more reliable due to the potential for loss of MeSH subheadings when mapping to Emtree and the risk of false negatives and positives when searching Embase alone. Literature searches support signal detection and periodic evaluation of a product's safety profile.
Clinical research and pharmacovigilance biopharmaceutics
Clinical research involves systematically studying new drugs in human subjects to determine their safety and efficacy. It generates data on a drug's clinical, pharmacological, and adverse effects. Clinical trials are one type of clinical research that follows a predefined plan or protocol. Pharmacovigilance aims to protect public health by identifying, evaluating, managing and minimizing drug safety issues to ensure the benefits outweigh the risks. It involves monitoring adverse drug reactions through programs like India's Pharmacovigilance Programme, which collects ADR data from hospitals nationwide to enhance drug safety methodologies.
Expectedness/Unexpectedness Assessment_Katalyst HLS
Introduction to Expectedness/Unexpectedness Assessment in Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Rajath (1)
The FDA regulates pharmacovigilance for drugs in the US through various reporting requirements and guidelines. Reports of adverse events are collected in the FDA's Adverse Event Reporting System (AERS) database. The FDA's Office of Surveillance and Epidemiology oversees pharmacovigilance and is comprised of three divisions that monitor postmarketing drug safety. Manufacturers are required to submit periodic safety reports, while healthcare providers and consumers can voluntarily report adverse events. The FDA analyzes AERS data to identify safety issues and communicate findings to promote public health.
Outsourcing bioavailibility and bioequivalence studies to contract research
This document defines a contract research organization (CRO) and outlines their goals and services. CROs provide outsourced clinical research services to the pharmaceutical industry. Their services include clinical trials, preclinical research, pharmacovigilance, and biological assay development. Companies outsource to CROs due to lack of in-house capacity, skills, or to control costs. When selecting a CRO, companies should assess their clinical, bioanalytical, and pharmacokinetic capabilities. They should also qualify CRO sites to ensure compliance with Good Clinical Practices and laboratory standards.
Drug Information Association Clinical Forum Presentation
Pharmacoepidemiology studies were performed on YASMIN and CRESTOR to better understand safety risks in real-world use. For YASMIN, a large database study found no increased risks of hyperkalemia or blood clots compared to other oral contraceptives. For CRESTOR, a global program using multiple databases evaluated safety outcomes like rhabdomyolysis. Future directions may include using health databases and electronic records in large simple trials to efficiently answer safety questions.
Controlled drug release market to grow exponentially
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
Pharmacovigilance
Pharmacovigilance is the science of monitoring approved drugs to detect adverse effects. It aims to identify new risks, assess known risks, and prevent harm. Pharmacovigilance relies on collecting data on adverse drug reactions (ADRs) through passive and active methods. Data is analyzed to detect safety signals and assess risks and benefits of medicines to optimize safe use. Regulatory authorities use pharmacovigilance data to take actions like updating product information or withdrawing approval if risks outweigh benefits.
Premarket Clinical Evaluation under the EU MDR proposal
The document summarizes the proposed EU regulation for medical devices which would combine existing directives and require more extensive premarket clinical evaluation for class IIb and III devices. It outlines that clinical trials would be needed to demonstrate safety, efficacy and intended use in the target population according to claims. Existing evidence and device equivalence must also be established, with controls and trials designed based on best practices in the primary market. The regulation aims to demand a higher level of clinical evidence for medical device approval.
Biologics market
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Drug Safety Regulations In The Us And Eu
This document provides an overview of pharmacovigilance systems and regulations in the US and EU. It describes regulatory oversight bodies, key regulations governing pharmacovigilance, safety reporting requirements during pre-marketing and post-marketing periods, pediatric legislation differences, and risk management strategies between the regions.
pharmacovigilance in india-by dr.nagaraja prasad.s
This document discusses pharmacovigilance in India, both past and present. It notes that India did not previously have a formal pharmacovigilance system, but initiated activities in 1986 and joined the WHO program in 1997. The National Pharmacovigilance Program was launched in 2004 and became operational in 2005. It has since expanded to include 90 monitoring centers across India. The program aims to ensure drug safety, identify new adverse drug reactions, and support regulatory decision making. Future prospects include expanding the program further and implementing hemovigilance and biovigilance initiatives to monitor blood and medical devices.
Post marketing surveilance
PMS are the studies done after the drug is marketed to ensure the safety and efficacy of drugs. Here detailed about the need for PMS, sources of informations and methods of PMS
Pharmacovigilance System in Pakistan
The document discusses pharmacovigilance, which is defined as the science of detecting, assessing, understanding, and preventing adverse effects of medicines. It describes the history of pharmacovigilance, including the thalidomide tragedy in the 1960s which led to increased regulation. The document outlines pharmacovigilance in Pakistan, including the establishment of an online reporting system by DRAP in 2018 for healthcare professionals and patients to report adverse drug reactions. It provides key terms related to pharmacovigilance and describes the pharmacovigilance workflow and functions.
Post marketing surveillance
This document discusses post-marketing surveillance (PMS), which involves monitoring drugs after they reach the market to detect previously unrecognized effects. PMS is important for safety and improving products. Key goals are identifying adverse effects and characterizing incidence rates. Several methods are used in PMS, including voluntary reporting, controlled trials, cohort studies, and case-control studies. Cohort studies follow groups over time to assess outcomes, while case-control studies compare exposure rates between those with and without a disease. PMS provides real-world evidence on drug performance and benefits patients.
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
This document discusses factors that contribute to irrational drug use and increased healthcare costs. It identifies 10 reasons for rising healthcare expenses, with numbers 3 through 10 adding no value. These include action without evidence, regulations and compliance costs, inefficiency, perverse incentives, defensive medicine, errors, profits taken from the system, and fraud. The document also discusses issues with drug promotion and marketing, medical journals' dependence on pharmaceutical advertising, and the manipulation of scientific studies. Overall, it examines the influence of industry on prescribing practices and the lack of evidence-based pharmacotherapy.
ICH GCP
The document discusses the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guideline.
ICH-GCP is an international ethical and scientific quality standard for clinical trials involving human subjects. It aims to ensure trials are scientifically sound and respect the rights, safety and well-being of participants. The guideline was developed in response to medical tragedies and the need for harmonized standards across regions to facilitate global drug development. It outlines principles for conducting clinical trials, including obtaining informed consent and ensuring confidentiality. Adherence to ICH-GCP provides assurance that clinical trial data are credible and that participants are adequately protected.
More Related Content
What's hot
Pharmacovigilance systems & methodologies across the globe
The document discusses various pharmacovigilance systems and methodologies used around the world to monitor the safety of medicines. It describes the WHO global database VigiBase which contains reports of adverse drug reactions. It also outlines other pharmacovigilance systems like EudraVigilance in Europe, FAERS in the US, Canada Vigilance in Canada, and the Yellow Card Scheme in the UK. The document then discusses data mining and analysis techniques used for pharmacovigilance, including those for pre-marketing surveillance using computational approaches as well as those for post-marketing surveillance using spontaneous reporting systems, electronic health records, and non-traditional data sources.
Market impact of WHO selection and prequalification of priority medicines
Presentation with the occasion of the Technical Briefing at World Halth Assembly, Geneva, 18 May 2011
Pharmacovigilance
Pharmacovigilance is the science of monitoring approved drugs to detect adverse effects. It aims to improve patient safety by understanding drug risks. Clinical trials cannot detect all risks due to limited size and duration. Spontaneous reporting allows healthcare providers to report suspected adverse drug reactions. Limitations of clinical data and withdrawals like thalidomide led to pharmacovigilance programs worldwide including the WHO program and national programs in India, UK, and US. Pharmacovigilance involves collecting, analyzing, and communicating safety information to improve patient therapy and public health.
Pharmacovigilance - a regulator's perspective
The document discusses pharmacovigilance from the perspective of the Therapeutic Goods Administration (TGA) in Australia. It provides an overview of the TGA's pharmacovigilance activities, including pre-market risk management plans and post-market adverse event reporting and signal detection. It describes how the TGA monitors the safety of medicines throughout their lifecycle to identify new or unknown risks following approval.
Post marketing servillence
This document discusses post-marketing surveillance (PMS), which involves monitoring the safety of pharmaceutical drugs and medical devices after they have been approved and released on the market. PMS is important because pre-approval clinical trials involve limited numbers of patients and cannot detect all potential adverse effects. The document outlines the history of PMS, sources of PMS information, benefits of PMS systems, methods of surveillance including spontaneous reporting and cohort studies, and how manufacturers can establish PMS procedures and systems to gather feedback on their products.
Literature monitoring for pv what are we doing at galderma elsevier webinar
The document discusses literature monitoring for pharmacovigilance. It describes weekly monitoring of individual case safety reports and periodic monitoring through development safety update reports and periodic benefit-risk evaluation reports. Key databases for literature searches are Medline and Embase. While Embase has more extensive drug coverage, searches on Medline via PubMed are more reliable due to the potential for loss of MeSH subheadings when mapping to Emtree and the risk of false negatives and positives when searching Embase alone. Literature searches support signal detection and periodic evaluation of a product's safety profile.
Clinical research and pharmacovigilance biopharmaceutics
Clinical research involves systematically studying new drugs in human subjects to determine their safety and efficacy. It generates data on a drug's clinical, pharmacological, and adverse effects. Clinical trials are one type of clinical research that follows a predefined plan or protocol. Pharmacovigilance aims to protect public health by identifying, evaluating, managing and minimizing drug safety issues to ensure the benefits outweigh the risks. It involves monitoring adverse drug reactions through programs like India's Pharmacovigilance Programme, which collects ADR data from hospitals nationwide to enhance drug safety methodologies.
Expectedness/Unexpectedness Assessment_Katalyst HLS
Introduction to Expectedness/Unexpectedness Assessment in Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Rajath (1)
The FDA regulates pharmacovigilance for drugs in the US through various reporting requirements and guidelines. Reports of adverse events are collected in the FDA's Adverse Event Reporting System (AERS) database. The FDA's Office of Surveillance and Epidemiology oversees pharmacovigilance and is comprised of three divisions that monitor postmarketing drug safety. Manufacturers are required to submit periodic safety reports, while healthcare providers and consumers can voluntarily report adverse events. The FDA analyzes AERS data to identify safety issues and communicate findings to promote public health.
Outsourcing bioavailibility and bioequivalence studies to contract research
This document defines a contract research organization (CRO) and outlines their goals and services. CROs provide outsourced clinical research services to the pharmaceutical industry. Their services include clinical trials, preclinical research, pharmacovigilance, and biological assay development. Companies outsource to CROs due to lack of in-house capacity, skills, or to control costs. When selecting a CRO, companies should assess their clinical, bioanalytical, and pharmacokinetic capabilities. They should also qualify CRO sites to ensure compliance with Good Clinical Practices and laboratory standards.
Drug Information Association Clinical Forum Presentation
Pharmacoepidemiology studies were performed on YASMIN and CRESTOR to better understand safety risks in real-world use. For YASMIN, a large database study found no increased risks of hyperkalemia or blood clots compared to other oral contraceptives. For CRESTOR, a global program using multiple databases evaluated safety outcomes like rhabdomyolysis. Future directions may include using health databases and electronic records in large simple trials to efficiently answer safety questions.
Controlled drug release market to grow exponentially
“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:
Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 451
Drug Profile in Active Clinical Phase (Research till Registration): 234
Majority of Controlled Release Drug in Phase-II Development: 58
Marketed Controlled Release Drugs: 140
Suspended & Discontinued Drug Profiles
Pharmacovigilance
Pharmacovigilance is the science of monitoring approved drugs to detect adverse effects. It aims to identify new risks, assess known risks, and prevent harm. Pharmacovigilance relies on collecting data on adverse drug reactions (ADRs) through passive and active methods. Data is analyzed to detect safety signals and assess risks and benefits of medicines to optimize safe use. Regulatory authorities use pharmacovigilance data to take actions like updating product information or withdrawing approval if risks outweigh benefits.
Premarket Clinical Evaluation under the EU MDR proposal
The document summarizes the proposed EU regulation for medical devices which would combine existing directives and require more extensive premarket clinical evaluation for class IIb and III devices. It outlines that clinical trials would be needed to demonstrate safety, efficacy and intended use in the target population according to claims. Existing evidence and device equivalence must also be established, with controls and trials designed based on best practices in the primary market. The regulation aims to demand a higher level of clinical evidence for medical device approval.
Biologics market
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Drug Safety Regulations In The Us And Eu
This document provides an overview of pharmacovigilance systems and regulations in the US and EU. It describes regulatory oversight bodies, key regulations governing pharmacovigilance, safety reporting requirements during pre-marketing and post-marketing periods, pediatric legislation differences, and risk management strategies between the regions.
pharmacovigilance in india-by dr.nagaraja prasad.s
This document discusses pharmacovigilance in India, both past and present. It notes that India did not previously have a formal pharmacovigilance system, but initiated activities in 1986 and joined the WHO program in 1997. The National Pharmacovigilance Program was launched in 2004 and became operational in 2005. It has since expanded to include 90 monitoring centers across India. The program aims to ensure drug safety, identify new adverse drug reactions, and support regulatory decision making. Future prospects include expanding the program further and implementing hemovigilance and biovigilance initiatives to monitor blood and medical devices.
Post marketing surveilance
PMS are the studies done after the drug is marketed to ensure the safety and efficacy of drugs. Here detailed about the need for PMS, sources of informations and methods of PMS
Pharmacovigilance System in Pakistan
The document discusses pharmacovigilance, which is defined as the science of detecting, assessing, understanding, and preventing adverse effects of medicines. It describes the history of pharmacovigilance, including the thalidomide tragedy in the 1960s which led to increased regulation. The document outlines pharmacovigilance in Pakistan, including the establishment of an online reporting system by DRAP in 2018 for healthcare professionals and patients to report adverse drug reactions. It provides key terms related to pharmacovigilance and describes the pharmacovigilance workflow and functions.
Post marketing surveillance
This document discusses post-marketing surveillance (PMS), which involves monitoring drugs after they reach the market to detect previously unrecognized effects. PMS is important for safety and improving products. Key goals are identifying adverse effects and characterizing incidence rates. Several methods are used in PMS, including voluntary reporting, controlled trials, cohort studies, and case-control studies. Cohort studies follow groups over time to assess outcomes, while case-control studies compare exposure rates between those with and without a disease. PMS provides real-world evidence on drug performance and benefits patients.
What's hot (20)
Pharmacovigilance systems & methodologies across the globe
Pharmacovigilance systems & methodologies across the globe
Market impact of WHO selection and prequalification of priority medicines
Market impact of WHO selection and prequalification of priority medicines
Literature monitoring for pv what are we doing at galderma elsevier webinar
Literature monitoring for pv what are we doing at galderma elsevier webinar
Clinical research and pharmacovigilance biopharmaceutics
Clinical research and pharmacovigilance biopharmaceutics
Expectedness/Unexpectedness Assessment_Katalyst HLS
Expectedness/Unexpectedness Assessment_Katalyst HLS
Outsourcing bioavailibility and bioequivalence studies to contract research
Outsourcing bioavailibility and bioequivalence studies to contract research
Drug Information Association Clinical Forum Presentation
Drug Information Association Clinical Forum Presentation
Controlled drug release market to grow exponentially
Controlled drug release market to grow exponentially
Premarket Clinical Evaluation under the EU MDR proposal
Premarket Clinical Evaluation under the EU MDR proposal
pharmacovigilance in india-by dr.nagaraja prasad.s
pharmacovigilance in india-by dr.nagaraja prasad.s
Similar to Open Data In Clinical Research
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
This document discusses factors that contribute to irrational drug use and increased healthcare costs. It identifies 10 reasons for rising healthcare expenses, with numbers 3 through 10 adding no value. These include action without evidence, regulations and compliance costs, inefficiency, perverse incentives, defensive medicine, errors, profits taken from the system, and fraud. The document also discusses issues with drug promotion and marketing, medical journals' dependence on pharmaceutical advertising, and the manipulation of scientific studies. Overall, it examines the influence of industry on prescribing practices and the lack of evidence-based pharmacotherapy.
ICH GCP
The document discusses the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guideline.
ICH-GCP is an international ethical and scientific quality standard for clinical trials involving human subjects. It aims to ensure trials are scientifically sound and respect the rights, safety and well-being of participants. The guideline was developed in response to medical tragedies and the need for harmonized standards across regions to facilitate global drug development. It outlines principles for conducting clinical trials, including obtaining informed consent and ensuring confidentiality. Adherence to ICH-GCP provides assurance that clinical trial data are credible and that participants are adequately protected.
MAGI West 2010 Presentation Final
The document summarizes information from MAGI's Clinical Research Conference about conducting clinical trials in Russia, Eastern Europe, Ukraine, Romania, Bulgaria, and the Czech Republic. Some key points discussed include:
- Russia and Eastern Europe have become increasingly experienced sites for clinical trials, often outperforming sites in Europe and North America in terms of enrollment and quality.
- Countries in the region generally adhere to Western European drug law standards or ICH-GCP guidelines. Sites are experienced following these guidelines with high recruitment rates and low dropout.
- Over the past 10-20 years, the number of approved clinical trials has steadily increased across the countries discussed, with oncology, circulatory systems, and CNS
Affitech
Affitech A/S is a biotech company developing fully human therapeutic antibodies using its proprietary CBASTM platform. It has a lead anti-VEGF antibody candidate, AT001/r84, that selectively inhibits VEGF binding and has shown efficacy in preclinical models. Affitech has additional antibody programs targeting GPCRs for cancer and inflammation. It has strategic partnerships for several candidates and research collaborations to advance its pipeline and antibody platform.
Clinical Rubik's Cube: Global Clinical Trials in Hungary
Global clinical research opportunities and challenges. Example of Hungary- clinical trials growth, data quality, ethics approvals, investigator landscape
Turkiyede klinik arastirma 2015 ing
This document provides an overview of clinical trials in Turkey. It discusses the history and evolution of regulations governing clinical trials from the 1920s to present day. Key events include the first regulations in 1928, formation of ethics committees in 1993, and adoption of ICH-GCP guidelines in 1995. The infrastructure for clinical trials in Turkey has grown significantly in recent decades with over 100 ethics committees and several phase I centers. Inspections by regulatory authorities like the FDA and EMA have increased transparency. Current regulations aim to protect participants and uphold ethical standards in research.
Stage IIB carcinoma of the cervix that is associated with pelvic kidney: Athe...
The document discusses potential applications of peptides as biotherapeutic tools, including:
1) Using opioid growth factor (OGF) to treat pancreatic and head and neck cancers by inhibiting cancer growth.
2) Developing antibodies and ELISA kits to detect OGF receptors to aid in diagnosis and screening for cancers.
3) Applying the opioid antagonist naltrexone to accelerate wound healing in conditions like diabetic wounds.
Clinical trials and research partnerships are underway or planned for these applications.
PEPTIDES AS BIOTHERAPEUTIC TOOLS PEPTIDES AS BIOTHERAPEUTIC TOOLS
The document discusses potential biotherapeutic applications of opioid growth factor (OGF) and its receptor (OGFr) for treating several cancers and diabetic wounds. It outlines clinical trials and milestones achieved using OGF to treat pancreatic and head and neck cancers. It also discusses using the opioid antagonist naltrexone to accelerate wound healing in diabetes. Potential market sizes are provided for pancreatic cancer, head and neck cancer, and diabetic wound healing applications.
Ich
The document discusses the International Council for Harmonization (ICH). ICH aims to harmonize technical requirements for pharmaceutical product registration among regulators in Europe, Japan, and the United States to reduce duplication of testing and make the development of new medicines more efficient. It outlines the structure of ICH, including its steering committee and expert working groups. ICH guidelines cover quality, safety, efficacy, and multidisciplinary topics. The overall goal is to streamline drug development while maintaining high standards for safety, quality and efficacy.
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric RaymondProf. Eric Raymond Oncologie Medicale
Pharmacology Forever ! has been set as a meeting in recognition of Frits Peters tremendous involvement in pharmacology. This presentation discusses latest drug development methods and is illustrated by exemple of new drugs and target in oncology.Knowledge is Power: ovarian cancer
The document discusses a clinical trial called GOG 218 that evaluated the use of the drug bevacizumab for the primary treatment of advanced epithelial ovarian cancer. The trial found that patients who received bevacizumab plus chemotherapy had a 3 month improvement in progression-free survival compared to those who received chemotherapy alone. Bevacizumab is the first molecular targeted therapy and anti-angiogenic agent to demonstrate a benefit in upfront treatment of ovarian cancer. While survival was not yet improved, the trial provides support for further research evaluating bevacizumab and other targeted agents to improve outcomes for ovarian cancer patients.
2008 global development korea's perspective and the role of kfda
The global pharmaceutical market has grown steadily, reaching $602 trillion KRW in 2005 and expected to reach $900 trillion KRW by 2010. The US market leads at 45% share, while the Chinese market is growing the fastest at 30%. Korea's pharmaceutical market, while smaller at 1.8% of the global market, has also grown rapidly. Korea has developed infrastructure for clinical trials and new drug development. To further contribute to regional growth, Korea proposes establishing cooperation between Korea, China, and Japan to more quickly deliver new drugs to patients and to reflect Eastern values, utilizing their geographic and cultural similarities. The Korea Food and Drug Administration will pursue global harmonization while focusing cooperation on natural substances, herbal medicine, and clinical trials
Forsythe protocol 2014 summit
The Forsythe Immune Protocol ™
The Forsythe Lite LDIPT Protocol ™
Out-Come Based Investigation
600 Patients - 48 Months
From 06/10 - 06/14
Using CST
2014 09-10 ACI biomarker utilisation & commercialisation, London
This document summarizes a presentation given by Professor Alain van Gool on biomarkers in personalized healthcare. It discusses the evolving role of biomarkers from diagnosis to personalized medicine. It provides examples of how biomarkers help target melanoma treatment and analyze the complex system of metabolic health and disease. The presentation argues for a systems approach combining pharmaceutical, nutritional and lifestyle therapies informed by biomarkers.
Highlights from ExL Pharma's 5th Clinical Data Disclosure Summit
This document summarizes highlights from ExLPharma's 5th Clinical Data Disclosure Summit in January 2010. It discusses:
- Growing requirements for clinical trial transparency in many countries and regions.
- EudraCT, the European clinical trials database, which currently allows sharing of information between European regulators but not public access. Plans are discussed to make it publicly accessible.
- Challenges involved in making EudraCT suitable for public access, including determining what information to release and when, how to handle trials conducted outside the EU, and developing common data standards.
Presentation from Dr. Alan Lewis
Alan J. Lewis, PhD. PowerPoint presentation from JDRF's Tenth Annual Spring Research Briefing and Reception.
Brian Ager - Selling Sickness 2010
The document discusses the importance of the pharmaceutical industry to Europe. It summarizes that the industry directly employs over 630,000 people in Europe and contributes 3.5% of EU manufacturing value. It is one of the few remaining high-technology industries in Europe. The industry also plays a dual role as a major economic contributor and in improving health outcomes for European citizens. However, access to new medicines remains a challenge due to the high costs of research and regulatory hurdles.
translational biotechnology-Amgen -Geeta Iyer -4-48-16
The document provides an overview of biotechnology company Amgen, including its introduction, current management, awards won in 2016, top-selling drugs like Epogen and Neupogen, and controversial issues. It discusses Amgen's collaborations with NASA on bone loss research and its strengths such as its large sales profits and patent portfolio. It also lists some risks facing Amgen like competition and potential challenges to its intellectual property.
Μάκης Παπαταξιάρχης - 6th Clinical Research Conference
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
This chapter discusses tumor markers for liver cancer. Liver cancer, or hepatocellular carcinoma, is a major cause of cancer death worldwide. Early detection is important for effective treatment but many cases are asymptomatic and detected late. The guidelines evaluate tumor markers like alpha-fetoprotein for surveillance of high-risk patients and diagnosis of liver cancer, noting their limitations. Recommendations are provided on the appropriate use of tumor markers in conjunction with imaging for managing liver cancer.
Similar to Open Data In Clinical Research (20)
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
Clinical Rubik's Cube: Global Clinical Trials in Hungary
Clinical Rubik's Cube: Global Clinical Trials in Hungary
Stage IIB carcinoma of the cervix that is associated with pelvic kidney: Athe...
Stage IIB carcinoma of the cervix that is associated with pelvic kidney: Athe...
PEPTIDES AS BIOTHERAPEUTIC TOOLS PEPTIDES AS BIOTHERAPEUTIC TOOLS
PEPTIDES AS BIOTHERAPEUTIC TOOLS PEPTIDES AS BIOTHERAPEUTIC TOOLS
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
2008 global development korea's perspective and the role of kfda
2008 global development korea's perspective and the role of kfda
2014 09-10 ACI biomarker utilisation & commercialisation, London
2014 09-10 ACI biomarker utilisation & commercialisation, London
Highlights from ExL Pharma's 5th Clinical Data Disclosure Summit
Highlights from ExL Pharma's 5th Clinical Data Disclosure Summit
translational biotechnology-Amgen -Geeta Iyer -4-48-16
translational biotechnology-Amgen -Geeta Iyer -4-48-16
Μάκης Παπαταξιάρχης - 6th Clinical Research Conference
Μάκης Παπαταξιάρχης - 6th Clinical Research Conference
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
More from Martin Fenner
ORCID Principles
1) ORCID is a non-profit organization that launched in 2010 to create a central registry of researcher identities and link them to contributions such as publications, datasets, and patents.
2) ORCID aims to support reliable attribution of authors and enable discovery and evaluation of researchers' scholarly works by transcending boundaries and making profile data freely available in standard and open formats.
3) ORCID will be sustained through a combination of free and fee-based services, with fees set to ensure its long-term viability as a not-for-profit focused on persistent identification.
Tools for Authors 18.01.11
The document discusses simplifying the scholarly publishing workflow by using HTML instead of other formats like PDF, DOC, XML. It notes problems with the traditional workflow like being slow, expensive, and boring. The simplified workflow involves submission and publication using just HTML. Reasons HTML is preferable include that it is widely used, doesn't require well-formed markup, and focuses on linking between documents. The document provides examples of tools that can be used with HTML and suggests starting with HTML in WordPress using plugins for reference management and other functions.
Repositories: Researcher Perspective
Researchers primarily publish their work to communicate results to their peer community so that others can read and build upon their findings. While advancing their career and gaining prestige or funding are also motivations, researchers consider communicating their results as their top priority. However, there remains a disconnect between researchers and how easily they can search across institutional repositories to find relevant results. Improving integration tools and identifiers for researchers may help address this issue.
ORCID Outreach Working Group
The Outreach Working Group had a participant meeting on November 18, 2010. The meeting provided an update on the ORCID initiative including a name change from the Marketing Working Group. Participant organization types and geographic locations were reported. A survey found blogs/online, webinars, and conferences to be the best ways to inform participants of developments over the next 12 months. The agenda for the next three months includes creating more information material, updating the website, increasing opportunities for discussion, increasing participation, building relationships with partners, building a participant database, and providing a contact email.
Helping Researchers Create Scholarly Content
The document summarizes key findings from a research article that analyzed the association between cancer prevalence and use of thiazolidinedione drugs in patients with diabetes. The summary is:
The study found that patients taking the thiazolidinedione drugs pioglitazone or rosiglitazone did not have a higher risk of cancer compared to those not taking the drugs. Patients with cancer tended to be older, have more comorbidities, and worse physical and mental functional status. The study provided univariate analysis of associations between cancer and various patient characteristics.
ORCID as unique author identifier: what is it good for and should we worry or...
Martin Fenner from the Department of Hematology submitted a manuscript. The submission process was reduced work through automated CVs, publication lists, and related works by author. Semantic analysis of authorship determined Fenner was the corresponding author who analyzed microarray data as the first author. A few example URLs were provided.
Trends in Reference Management
Presentation given at the Open University Innovations in Reference Management workshop June 21, 2010 in Birmingham
Open Access In Medicine
This document provides an overview of open access in medicine. It discusses two main forms of open access: gold OA which is publishing in an open access journal, and green OA which is self-archiving in an institutional repository or PubMed Central. It notes that PubMed Central provides open access to over 19 million citations and links to full-text articles. The document also discusses the NIH public access policy which requires researchers receiving NIH funds to submit final peer-reviewed manuscripts to PubMed Central. Overall, the summary provides a high-level introduction to open access models and policies in the medical literature.
Science Publishing - Reward and Reputation
The document outlines various factors that contribute to a scientist's career, including publishing research papers, obtaining grants and awards, teaching positions, conference talks, blogging and social media presence. It also discusses how reputation in science is often tied to publishing in high impact factor journals, which are measured by the number of citations to articles in the journal over the previous two years, with the impact factor calculated and owned by Thomson Reuters.
What is the right reference manager for you?
This document discusses key factors to consider when choosing a reference manager. It outlines features like search, share, store, read, write, and use that are important to evaluate. Reference managers can import references from databases, bookmarklets, directly from web pages. They allow sharing references between computers and users. Consider platform compatibility, file formats, organization options, and citation style support when selecting a reference manager. Evaluate costs, interfaces, and support to determine the best fit.
Author Id Survey
This document summarizes the results of a survey about author identifiers for scientists. The majority of respondents felt that author identifiers should have the primary purposes of enabling unique identification of authors and author profiles. Most felt the identifiers should be managed by a central organization like CrossRef or the National Library of Medicine, and that there should be a single unified author identifier system rather than multiple competing systems.
Providing public health and medical information to all
This document discusses various ways of providing public health and medical information to all, including open access to clinical trials and research, science journalism, blogging, social networking among scientists, and direct-to-consumer advertising. It aims to improve access to scientific information for both professionals and the general public.
More from Martin Fenner (12)
ORCID as unique author identifier: what is it good for and should we worry or...
ORCID as unique author identifier: what is it good for and should we worry or...
Providing public health and medical information to all
Providing public health and medical information to all
Recently uploaded
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Top mailing list providers in the USA.pptx
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
Recruiting in the Digital Age: A Social Media Masterclass
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Industrial Tech SW: Category Renewal and Creation
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka Indian satta Matka Dpboss Matka Kalyan Chart Matka Boss otg matka Guessing Satta Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS-- June 2024 is National Volunteer Month --
Check out our June display of books on voluntary organisations
An introduction to the cryptocurrency investment platform Binance Savings.
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Best practices for project execution and delivery
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
2024-6-01-IMPACTSilver-Corp-Presentation.pdf
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
ModelingMarketingStrategiesMKS.CollumbiaUniversitypdf
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Recently uploaded (20)
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdf
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
The Influence of Marketing Strategy and Market Competition on Business Perfor...
The Influence of Marketing Strategy and Market Competition on Business Perfor...
An introduction to the cryptocurrency investment platform Binance Savings.
An introduction to the cryptocurrency investment platform Binance Savings.
Training my puppy and implementation in this story
Training my puppy and implementation in this story
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
ModelingMarketingStrategiesMKS.CollumbiaUniversitypdf
ModelingMarketingStrategiesMKS.CollumbiaUniversitypdf
Open Data In Clinical Research
- 1. Clinical trial registration: a model for basic research? August 17, 2008 Version 1.0 Martin Fenner fenner.martin@mh-hannover.de Hannover Medical School, Germany
- 2. Rationale for registration of clinical trials • Improve trial participation by patients • Reduce unnecessary duplication of research efforts • Increase opportunities for collaboration • Prevent biased under-reporting or over-reporting of research Krleza-Jeric 2005. doi:10.1136/bmj.330.7497.956